Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Part of paid clinical trials in Evanston, Illinois.
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study ID
- NCT00588900
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- cediranib maleate — DRUG
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving irinotecan together with cediranib may kill more tumor cells. PURPOSE: This phase II clinical trial is studying how well giving irinotecan together with cediranib works in treating patients with metastatic colorectal cancer that did not respond to previous oxaliplatin, fluoropyrimidine, and bevacizumab.
Key Dates
- Start date
- Mar 31, 2008
- Status verified
- Mar 2017
- Primary completion
- May 31, 2010
- Completion
- Nov 30, 2011
Study Design
- Enrollment
- 5 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: irinotecan + cediranibPatients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry.
Primary Outcome Measure
The Percentage of Patients Who Are Progression-free at 12 Weeks From the Start of Second-line Therapy [ Time Frame: at 12 weeks ]
Locations (31)
Find similar trials in Evanston, IL
Related Studies
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid CancersRecruiting · University of Missouri-Columbia · Columbia, Missouri
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone MarrowRecruiting · University of Missouri-Columbia · Columbia, Missouri